Raymond James Upgrades Immunovant (IMVT) to Outperform, 'We view today’s MAD data as an important de-risking event'
Tweet Send to a Friend
(Updated - September 26, 2023 10:28 AM EDT)
Raymond James analyst Danielle Brill upgraded Immunovant (NASDAQ: IMVT) from to ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Raymond James analyst Danielle Brill upgraded Immunovant (NASDAQ: IMVT) from to ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
